Evidence map›Paper›PMID 28051998›Full record

ArticleOncotarget2017

PREX1 integrates G protein-coupled receptor and phosphoinositide 3-kinase signaling to promote glioblastoma invasion.

Alexander Gont, Manijeh Daneshmand, John Woulfe, Sylvie J Lavictoire, Ian A J Lorimer

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. The Role of Rho GTPases in Motility and Invasion of Glioblastoma Cells.Analytical cellular pathology (Amsterdam) · 2020
    Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Alexander GontCancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Canada.
Manijeh DaneshmandCancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Canada.
John WoulfeCancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Canada.
Sylvie J LavictoireCancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Canada.
Ian A J LorimerCancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Canada.
Ottawa Hospital Research InstituteUniversity of Ottawa · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A defining feature of the brain cancer glioblastoma is its highly invasive nature. When glioblastoma cells are isolated from patients using serum free conditions, they accurately recapitulate this invasive behaviour in animal models. The Rac subclass of Rho GTPases has been shown to promote invasive behaviour in glioblastoma cells isolated in this manner. However the guanine nucleotide exchange factors responsible for activating Rac in this context have not been characterized previously. PREX1 is a Rac guanine nucleotide exchange factor that is synergistically activated by binding of G protein αγ subunits and the phosphoinositide 3-kinase pathway second messenger phosphatidylinositol 3,4,5 trisphosphate. This makes it of particular interest in glioblastoma, as the phosphoinositide 3-kinase pathway is aberrantly activated by mutation in almost all cases. We show that PREX1 is expressed in glioblastoma cells isolated under serum-free conditions and in patient biopsies. PREX1 promotes the motility and invasion of glioblastoma cells, promoting Rac-mediated activation of p21-associated kinases and atypical PKC, which have established roles in cell motility. Glioblastoma cell motility was inhibited by either inhibition of phosphoinositide 3-kinase or inhibition of G protein βγ subunits. Motility was also inhibited by the generic dopamine receptor inhibitor haloperidol or a combination of the selective dopamine receptor D2 and D4 inhibitors L-741,626 and L-745,870. This establishes a role for dopamine receptor signaling via G protein βγ subunits in glioblastoma invasion and shows that phosphoinositide 3-kinase mutations in glioblastoma require a context of basal G protein-coupled receptor activity in order to promote this invasion.

Indexed as

Cell MovementSignal TransductionAntineoplastic AgentsBrain NeoplasmsCell Line, TumorDopamine AntagonistsDose-Response Relationship, DrugFemaleGene Expression Regulation, EnzymologicGene Expression Regulation, NeoplasticGlioblastomaGTP-Binding Protein beta SubunitsGTP-Binding Protein gamma SubunitsGuanine Nucleotide Exchange FactorsHumansMaleAntineoplastic AgentsDopamine AntagonistsG-protein Beta gammaGTP-Binding Protein beta SubunitsGTP-Binding Protein gamma SubunitsGuanine Nucleotide Exchange Factorsp21-Activated Kinasesphosphatidylinositol 3,4,5-triphosphatePhosphatidylinositol 3-KinasePhosphatidylinositol PhosphatesPhosphoinositide-3 Kinase InhibitorsPKC-3 proteinPREX1 protein, humanProtein Kinase CProtein Kinase Inhibitorsrac1 GTP-Binding ProteinRAC1 protein, humanReceptors, DopamineAbbreviations: GEFguanine nucleotide exchange factor

Identifiers

PMID28051998
PMCPMC5352422
OpenAlexW2563000383

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.